TL;DR: Both activate the GLP-1 receptor; only tirzepatide also activates GIP. That single structural difference is the whole comparison. In SURPASS-2 — the one head-to-head trial — tirzepatide produced larger reductions in both HbA1c and body weight, though against semaglutide's diabetes dose rather than its weight-management dose. Both are supplied for research use only.
New to these compounds? Start with our plain-language overview, Retatrutide vs Semaglutide vs Tirzepatide: A Simple Guide, then return here for the detail.
The One Structural Difference
Semaglutide is a selective agonist. It binds the GLP-1 receptor and switches on its downstream signal, and does not meaningfully engage the GIP receptor.
Tirzepatide is a dual agonist — a single molecule activating both the GLP-1 and GIP receptors. A detail that surprises people: its affinity for GIP is actually higher than its affinity for GLP-1. It is not a GLP-1 drug with GIP activity bolted on; if anything the emphasis runs the other way.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors | GLP-1 only | GLP-1 + GIP |
| Class | Selective agonist | Dual agonist |
| Half-life | ~165 hours (about a week) | ~120 hours (about five days) |
| Brand names | Ozempic, Wegovy | Mounjaro, Zepbound |
What GIP Adds
GIP — glucose-dependent insulinotropic polypeptide — is the other major incretin hormone. Like GLP-1 it is released from the gut after eating and amplifies glucose-dependent insulin secretion. Unlike GLP-1, it also acts directly on adipose tissue, influencing how fat cells handle incoming nutrients.
There is a genuine puzzle here worth flagging rather than smoothing over. GIP receptor agonism improved outcomes in the tirzepatide programme — but GIP receptor antagonism has also shown metabolic benefit in separate research. Both directions appearing to help is not what you would expect from a simple on-switch, and it suggests the receptor's role is context-dependent in ways the field has not resolved.
That both blocking and activating the same receptor can produce metabolic benefit is one of the more genuinely unresolved questions in incretin pharmacology.
Pharmacokinetics
Both are chemically modified to bind reversibly to serum albumin, a blood protein. That binding is what keeps them circulating for days rather than the roughly two-minute half-life of natural GLP-1 — the single engineering change that made this entire drug class viable.
Semaglutide's half-life of about 165 hours and tirzepatide's of about 120 hours both comfortably support once-weekly administration in published protocols. The difference between five and seven days has little practical consequence at weekly intervals.
What the Trials Found
This comparison is unusually well-served by evidence, because unlike most peptide comparisons it includes a genuine head-to-head study.
SURPASS-2 compared the two directly in type 2 diabetes and reported greater reductions in both HbA1c and body weight for tirzepatide across its dose arms.
One caveat is routinely dropped when this result is cited, and it matters: SURPASS-2 compared tirzepatide against semaglutide 1 mg — the type 2 diabetes dose — not the 2.4 mg dose used for weight management. So it is not the maximum-versus-maximum comparison it is often presented as. Tirzepatide's advantage in that trial is real, but its magnitude against semaglutide's highest dose is not what the trial measured.
Beyond it, the SURPASS programme characterizes tirzepatide and the SUSTAIN and STEP programmes remain the benchmark datasets for what selective GLP-1 activation does on its own.
Side Effect Profiles
Both share the gastrointestinal signature typical of the incretin class — nausea, vomiting, diarrhea, and constipation — and in both cases these are dose-dependent and cluster after dose increases, which is why published protocols escalate gradually rather than starting at target.
Published data do not show a dramatic qualitative difference between the two, though reported rates vary across trials and dose levels. Neither carries the glucagon-linked considerations that distinguish retatrutide, covered in our retatrutide side-effects article.
Choosing One as a Research Tool
For a researcher selecting between them, the question is mechanistic rather than about potency:
- Studying GLP-1 signalling in isolation → semaglutide is the cleaner model, because there is only one variable.
- Studying combined incretin activation → tirzepatide is the appropriate tool.
- Studying incretin plus glucagon → that is retatrutide's territory, covered in retatrutide vs tirzepatide.
They are not dose equivalents of one another, and treating a dual agonist as "stronger semaglutide" misreads the pharmacology. The extra receptor changes what is being studied, not just how much.
Where Retatrutide Fits
The class has continued past both. Retatrutide adds a third receptor — glucagon — on top of the two tirzepatide engages, and published Phase 2 data report the largest body-weight reductions in the class, though from an earlier trial stage. Our triple-agonist explainer covers the mechanism and the GLP-1 primer covers the class architecture.
Handling and Sourcing
As with any incretin peptide, reconstitution and storage discipline matters — errors there undermine an entire experimental campaign before it starts. Our reconstitution guide covers the concentration math, which applies equally to tirzepatide, and the peptide reconstitution calculator handles any vial and diluent combination.
Helix North supplies Tirzepatide 10 mg and Tirzepatide 20 mg as research materials with batch-specific HPLC purity verification. Semaglutide is not currently stocked. See the GLP research hub for the full range.
For Research Use Only
All discussion above describes clinical-trial research and compound pharmacology. Brand-name products are named only to clarify which compound each contains; they are prescription medicines available through licensed channels. Helix North supplies these compounds for research applications only — not for human or animal consumption, and nothing here constitutes medical, dosing, or clinical guidance.
